Literature DB >> 8660845

Antigen-driven peripheral immune tolerance: suppression of experimental autoimmmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen.

A al-Sabbagh1, P A Nelson, Y Akselband, R A Sobel, H L Weiner.   

Abstract

Antigen-driven tolerance is an effective method of suppressing cell-mediated immune responses. We have previously demonstrated that exposure of gut-associated lymphoid tissue to myelin basic protein (MBP) via oral administration suppresses experimental autoimmune encephalomyelitis (EAE). To further study presentation of antigen to the immune system by mucosal surfaces as a method of antigen-driven tolerance, the effect of inhalation of MBP was investigated. MBP was given as an aerosol to Lewis rats on Days -10, -7, -5, and -3 prior to immunization with MBP in Freund's adjuvant and on Days 0, 2, and 4 following immunization. Aerosolization of MBP completely abrogated clinical EAE in 100% of treated rats. Central nervous system inflammation and delayed-type hypersensitivity and antibody responses to MBP were also significantly reduced in aerosol-treated animals. Aerosolization of histone, a basic protein of similar weight and charge as MBP, had no effect. Disease was also suppressed with one aerosol treatment on Day -3 or by administering MBP nasally. Aerosolization was more effective than oral administration of MBP over a wide dose range (0.005-5 mg). Splenic T cells isolated from animals postaerosolization adoptively transferred protection to naive animals immunized with MBP. Aerosolization of MBP to animals with relapsing EAE after recovery from the first attack decreased the severity of a subsequent attack. Aerosol and oral MBP were equally effective at suppressing the in vitro immune response as measured by proliferation and interferon-gamma production. We then tested aerosolization of a different autoantigen in a different disease model and found that aerosolization of type II collagen was effective in suppressing collagen-induced arthritis. Thus, aerosolization of an autoantigen is a potent method to downregulate an experimental T cell-mediated autoimmune disease and suggests that exposure of antigen to lung mucosal surfaces preferentially generates immunologic tolerance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660845     DOI: 10.1006/cimm.1996.0180

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

1.  Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice.

Authors:  C Aspord; C Thivolet
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

Review 2.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

3.  Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.

Authors:  D Teitelbaum; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 4.  Vaccination strategies for mucosal immune responses.

Authors:  P L Ogra; H Faden; R C Welliver
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia.

Authors:  K J Becker; R M McCarron; C Ruetzler; O Laban; E Sternberg; K C Flanders; J M Hallenbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

6.  Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.

Authors:  P I Karachunski; N S Ostlie; D K Okita; B M Conti-Fine
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

7.  Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.

Authors:  S H Im; D Barchan; S Fuchs; M C Souroujon
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

8.  Bystander suppression of murine collagen-induced arthritis by long-term nasal administration of a self type II collagen peptide.

Authors:  S Bayrak; N A Mitchison
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

9.  Dose-dependent mechanisms relate to nasal tolerance induction and protection against experimental autoimmune encephalomyelitis in Lewis rats.

Authors:  H L Li; J Q Liu; X F Bai; P H vn der Meide; H Link
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

Review 10.  Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.

Authors:  Cody D Moorman; Sue J Sohn; Hyewon Phee
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.